Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antibiotic Selection00:57

Antibiotic Selection

52.4K
Overview
52.4K
International Nursing Organizations II01:28

International Nursing Organizations II

975
The World Health Organization (WHO) is a specialized agency of the United Nations based in Geneva. The WHO has many initiatives that center around health. Primarily, they lead global efforts to expand universal health coverage using science-based policies and programs. They are also responsible for shaping health research agendas and developing norms and standards.
The WHO provides expert team support, including funding, vaccines, testing, and treatment tools at the country level to fight...
975

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Over-the-counter sales of high-priority antibiotics are common: results of a global survey.

JAC-antimicrobial resistance·2026
Same author

Meeting the 2024 UN General Assembly declaration targets on antimicrobial resistance.

Lancet (London, England)·2026
Same author

Impact of Aii Amacrine Cell Rewiring in a Pathoconnectome-Based Computational Model of Early Retinal Degeneration.

bioRxiv : the preprint server for biology·2026
Same author

Using oral and parenteral formulation of AWaRe antibiotics as a proxy estimate of community and hospital healthcare sector use.

JAC-antimicrobial resistance·2026
Same author

Interventions to address antimicrobial resistance in migrants: a systematic review.

JAC-antimicrobial resistance·2026
Same author

Overcoming Barriers to One Health Surveillance Implementation.

Health security·2026
Same journal

Why high scores do not mean application readiness for health AI.

Nature medicine·2026
Same journal

Polypill for heart failure with reduced ejection fraction: the POLY-HF randomized trial.

Nature medicine·2026
Same journal

Biological aging might help to explain the rising risk of early-onset cancer.

Nature medicine·2026
Same journal

Innate immune responsiveness predicts enhanced cellular immunity and symptomatic disease after controlled human influenza infection.

Nature medicine·2026
Same journal

A meta-analysis of the long-term effects of antihypertensive therapy on the risk of major cardiovascular disease across 51 randomized trials.

Nature medicine·2026
Same journal

Blood-based circular RNAs for early diagnosis of Alzheimer's disease.

Nature medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 14, 2025

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

1.6K

Advancing global antibiotic research, development and access.

Laura J V Piddock1, Yewande Alimi2, James Anderson3

  • 1Global Antibiotic Research and Development Partnership (GARDP), Geneva, Switzerland. lpiddock@gardp.org.

Nature Medicine
|September 3, 2024
PubMed
Summary
This summary is machine-generated.

The pipeline for new antibiotics is insufficient to combat rising drug-resistant infections. Increased public and philanthropic funding is crucial to incentivize antibiotic research and development (R&D) and ensure equitable access to treatments.

More Related Videos

Visual and Microscopic Evaluation of Streptomyces Developmental Mutants
08:42

Visual and Microscopic Evaluation of Streptomyces Developmental Mutants

Published on: September 12, 2018

17.9K
Author Spotlight: Advancing Antibiotic Resistance Research Using an Efflux-Deficient Bacterial Strain and a Single-Copy Gene Expression System
05:06

Author Spotlight: Advancing Antibiotic Resistance Research Using an Efflux-Deficient Bacterial Strain and a Single-Copy Gene Expression System

Published on: January 5, 2024

555

Related Experiment Videos

Last Updated: Jun 14, 2025

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

1.6K
Visual and Microscopic Evaluation of Streptomyces Developmental Mutants
08:42

Visual and Microscopic Evaluation of Streptomyces Developmental Mutants

Published on: September 12, 2018

17.9K
Author Spotlight: Advancing Antibiotic Resistance Research Using an Efflux-Deficient Bacterial Strain and a Single-Copy Gene Expression System
05:06

Author Spotlight: Advancing Antibiotic Resistance Research Using an Efflux-Deficient Bacterial Strain and a Single-Copy Gene Expression System

Published on: January 5, 2024

555

Area of Science:

  • * Infectious Diseases
  • * Pharmaceutical R&D
  • * Public Health Policy

Background:

  • * The global burden of drug-resistant infections is increasing, outpacing the development of new antibiotics.
  • * Economic challenges and declining private investment hinder antibiotic research and development (R&D).
  • * Antibiotic shortages and inequitable access to treatments are critical issues worldwide.

Purpose of the Study:

  • * To highlight the critical need for increased investment and commitment to antibiotic R&D.
  • * To emphasize the growing role of public and philanthropic funding in addressing antibiotic resistance.
  • * To advocate for policies ensuring equitable access to existing and novel antibiotic treatments.

Main Methods:

  • * Analysis of the current state of antibiotic R&D investment and challenges.
  • * Review of emerging public-private partnerships and funding models (e.g., CARB-X, GARDP, AMR Action Fund).
  • * Examination of innovative reimbursement and evaluation schemes for antibiotics.

Main Results:

  • * A significant gap exists between the need for new antibiotics and the current R&D pipeline.
  • * Public and philanthropic initiatives are increasingly vital in supporting antibiotic R&D.
  • * Innovative funding and access strategies are being piloted to address market failures.

Conclusions:

  • * Urgent global leadership and commitment are required to bolster the antibiotic R&D ecosystem.
  • * Incentivizing public health-driven R&D across all sectors is essential.
  • * Ensuring universal access to effective antibiotics must be a global priority.